AAHFN Educational Journal Club https://www.aahfn.org/members/blog_view.asp?id=1809922&rss=qQTJ45J5 Mon, 15 Jun 2026 07:05:18 GMT Tue, 22 Sep 2020 15:40:06 GMT Copyright © 2020 American Association of Heart Failure Nurses Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice https://www.aahfn.org/members/blog_view.asp?id=1809922&post=356387 https://www.aahfn.org/members/blog_view.asp?id=1809922&post=356387 Recording Link: https://fccdl.in/nJN3dm2cn6

Some discussion questions about this article to consider include:

1. Why is it important to distinguish between AL and ATTR-CM?

2. What are some of the red flags to think about when screening for ATTR-CM?

3. What is the next step in order to diagnose, once you have clinical suspicion
for ATTR-CM?

4. Can you discuss a case study with the group? Discussing case studies can help
to bring about awareness for this disease process and early recognition/diagnosis.

]]> Tue, 22 Sep 2020 16:40:06 GMT Amyloidosis https://www.aahfn.org/members/blog_view.asp?id=1809922&post=346404 https://www.aahfn.org/members/blog_view.asp?id=1809922&post=346404 Recording Link: https://fccdl.in/8Ne5BAsPXh

Some discussion questions about this article to consider include:

How does AL defer from ATTR amyloidosis?

How is AL amyloidosis diagnosed? Is blood work enough to establish a diagnosis? Why or why not?

Why is it important to co-manage AL amyloidosis patients? What specialties would you include in a multidisciplinary team?

What is the nursing role (both at the RN and APRN levels) in promoting health and therapy in patients with AL amyloidosis?

Thanks for join us today and I hope you join us in our blog for further discussion.

 

]]> Sun, 26 Apr 2020 21:22:44 GMT Cardiac Amyloidosis https://www.aahfn.org/members/blog_view.asp?id=1809922&post=335259 https://www.aahfn.org/members/blog_view.asp?id=1809922&post=335259 Cardiac Amyloidosis 

Recording Link: https://fccdl.in/9PgmLv0DDH

 

Knowledge Check Questions:

1. How do the types of amyloidosis impact prognosis and treatment?

2. What new therapies have emerged for treating ATTR amyloidosis? Why is this important?

3. What is the nursing role (both at the RN and APRN levels) in promoting health and therapy in our patients with amyloidosis?

4. Why do amyloidosis patients not tolerate typical GDMT for CHF?

]]> Tue, 19 Nov 2019 19:23:15 GMT